Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:BLTENASDAQ:JANXNASDAQ:MNMDNASDAQ:TARS On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBLTEBelite Bio$60.18+3.3%$61.09$38.80▼$86.53$1.92B-1.5250,461 shs37,274 shsJANXJanux Therapeutics$32.23+3.8%$29.97$22.52▼$71.71$1.90B3.27850,966 shs397,710 shsMNMDMind Medicine (MindMed)$6.36+2.1%$6.20$4.70▼$10.44$479.34M2.541.39 million shs478,328 shsTARSTarsus Pharmaceuticals$49.72-0.6%$47.60$20.08▼$57.28$1.91B0.94689,959 shs685,350 shs7 Energy Stocks to Buy and Hold ForeverWith the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBLTEBelite Bio+3.35%+10.04%-9.78%+1.76%+51.40%JANXJanux Therapeutics+3.80%+10.00%+10.76%-23.04%-31.99%MNMDMind Medicine (MindMed)+2.09%+12.37%+2.75%-14.40%-25.35%TARSTarsus Pharmaceuticals-0.56%+2.49%-3.90%-2.62%+55.18%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationBLTEBelite Bio2.9186 of 5 stars3.55.00.00.02.70.80.6JANXJanux Therapeutics2.9895 of 5 stars3.52.00.00.02.95.00.0MNMDMind Medicine (MindMed)2.5301 of 5 stars3.63.00.00.02.90.80.6TARSTarsus Pharmaceuticals2.2271 of 5 stars3.50.00.00.03.52.50.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceBLTEBelite Bio 3.00Buy$96.6760.63% UpsideJANXJanux Therapeutics 3.09Buy$95.25195.53% UpsideMNMDMind Medicine (MindMed) 3.23Buy$25.11294.83% UpsideTARSTarsus Pharmaceuticals 3.00Buy$63.6728.05% UpsideCurrent Analyst Ratings BreakdownLatest MNMD, BLTE, TARS, and JANX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails3/26/2025BLTEBelite BioBenchmarkSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$80.00 ➝ $80.003/18/2025BLTEBelite BioCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOverweight ➝ Overweight3/18/2025BLTEBelite BioHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$100.00 ➝ $100.003/7/2025MNMDMind Medicine (MindMed)Robert W. BairdSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOutperform ➝ Outperform$27.00 ➝ $16.003/7/2025MNMDMind Medicine (MindMed)HC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$55.00 ➝ $55.003/6/2025TARSTarsus PharmaceuticalsJefferies Financial GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$54.00 ➝ $58.003/3/2025JANXJanux TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$70.00 ➝ $70.002/28/2025JANXJanux TherapeuticsScotiabankSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetSector Perform ➝ Sector Perform$62.00 ➝ $41.002/28/2025JANXJanux TherapeuticsWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform$75.00 ➝ $76.002/26/2025TARSTarsus PharmaceuticalsBarclaysSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOverweight ➝ Overweight$62.00 ➝ $60.002/26/2025TARSTarsus PharmaceuticalsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$73.00 ➝ $73.00(Data available from 4/29/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookBLTEBelite BioN/AN/AN/AN/A$3.28 per shareN/AJANXJanux Therapeutics$10.59M179.92N/AN/A$7.46 per share4.32MNMDMind Medicine (MindMed)N/AN/AN/AN/A$1.90 per shareN/ATARSTarsus Pharmaceuticals$182.95M10.43N/AN/A$5.95 per share8.36Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateBLTEBelite Bio-$31.63M-$1.18N/AN/AN/AN/A-31.94%-30.73%5/12/2025 (Estimated)JANXJanux Therapeutics-$58.29M-$1.28N/AN/AN/A-463.91%-10.47%-9.86%5/6/2025 (Estimated)MNMDMind Medicine (MindMed)-$95.73M-$2.08N/AN/AN/AN/A-47.56%-35.55%5/8/2025 (Estimated)TARSTarsus Pharmaceuticals-$135.89M-$3.10N/AN/AN/A-103.64%-55.86%-39.28%5/6/2025 (Estimated)Latest MNMD, BLTE, TARS, and JANX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/14/2025Q1 2025TARSTarsus Pharmaceuticals-$0.75N/AN/AN/A$71.19 millionN/A5/12/2025Q1 2025BLTEBelite Bio-$0.37N/AN/AN/AN/AN/A5/8/2025Q1 2025MNMDMind Medicine (MindMed)-$0.36N/AN/AN/AN/AN/A5/6/2025Q1 2025JANXJanux Therapeutics-$0.42N/AN/AN/A$0.59 millionN/A3/17/2025Q4 2024BLTEBelite Bio-$0.30-$0.32-$0.02-$0.32N/AN/A3/6/2025Q4 2024MNMDMind Medicine (MindMed)-$0.33-$0.41-$0.08-$0.41N/AN/A2/27/2025Q4 2024JANXJanux Therapeutics-$0.49-$0.36+$0.13-$0.36N/AN/A2/25/2025Q4 2024TARSTarsus Pharmaceuticals-$0.68-$0.60+$0.08-$0.60$58.80 million$66.41 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthBLTEBelite BioN/AN/AN/AN/AN/AJANXJanux TherapeuticsN/AN/AN/AN/AN/AMNMDMind Medicine (MindMed)N/AN/AN/AN/AN/ATARSTarsus PharmaceuticalsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioBLTEBelite BioN/A30.7330.73JANXJanux TherapeuticsN/A38.8038.80MNMDMind Medicine (MindMed)0.099.009.00TARSTarsus Pharmaceuticals0.305.425.38Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipBLTEBelite Bio0.53%JANXJanux Therapeutics75.39%MNMDMind Medicine (MindMed)27.91%TARSTarsus Pharmaceuticals90.01%Insider OwnershipCompanyInsider OwnershipBLTEBelite Bio13.29%JANXJanux Therapeutics29.40%MNMDMind Medicine (MindMed)2.26%TARSTarsus Pharmaceuticals8.25%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableBLTEBelite Bio1031.84 million27.61 millionNot OptionableJANXJanux Therapeutics3059.11 million37.05 millionOptionableMNMDMind Medicine (MindMed)4075.37 million71.68 millionOptionableTARSTarsus Pharmaceuticals5038.38 million35.07 millionOptionableMNMD, BLTE, TARS, and JANX HeadlinesRecent News About These CompaniesTarsus Pharmaceuticals, Inc. (NASDAQ:TARS) Given Consensus Rating of "Buy" by BrokeragesApril 29 at 2:37 AM | marketbeat.comBoothbay Fund Management LLC Reduces Position in Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS)April 28 at 6:46 AM | marketbeat.comGilder Gagnon Howe & Co. LLC Buys 397,190 Shares of Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS)April 28 at 6:29 AM | marketbeat.comLord Abbett & CO. LLC Increases Position in Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS)April 28 at 5:56 AM | marketbeat.comLPL Financial LLC Sells 5,125 Shares of Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS)April 28 at 3:09 AM | marketbeat.comTarsus Pharmaceuticals, Inc. (NASDAQ:TARS) Shares Acquired by Wells Fargo & Company MNApril 26 at 3:18 AM | marketbeat.comTarsus Pharmaceuticals, Inc. (NASDAQ:TARS) Shares Bought by Canada Pension Plan Investment BoardApril 25, 2025 | marketbeat.comTarsus Pharmaceuticals to Host Live Webcast for Q1 2025 Financial Results and Corporate UpdateApril 24, 2025 | quiverquant.comTarsus to Report First Quarter 2025 Financial Results on Thursday, May 1, 2025April 24, 2025 | globenewswire.comSilverarc Capital Management LLC Grows Holdings in Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS)April 24, 2025 | marketbeat.comDiadema Partners LP Makes New $3.32 Million Investment in Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS)April 24, 2025 | marketbeat.comTarsus Pharmaceuticals to present abstracts on XDEMVY at ASCRS meetingApril 24, 2025 | markets.businessinsider.comRock Springs Capital Management LP Invests $6.14 Million in Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS)April 23, 2025 | marketbeat.comTarsus to Present Several Scientific Abstracts Highlighting the Global Prevalence of Demodex Blepharitis and the Clinical Impact of XDEMVY at the American Society of Cataract and Refractive Surgery (ASCRS) 2025 Annual MeetingApril 22, 2025 | globenewswire.comOC Drugmakers Grow Workforce 7%April 21, 2025 | ocbj.comAlpha DNA Investment Management LLC Purchases New Position in Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS)April 21, 2025 | marketbeat.comXTX Topco Ltd Takes Position in Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS)April 21, 2025 | marketbeat.comTarsus Pharmaceuticals, Inc. (NASDAQ:TARS) Shares Sold by JPMorgan Chase & Co.April 19, 2025 | marketbeat.comEAM Investors LLC Makes New Investment in Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS)April 18, 2025 | marketbeat.comTarsus Pharmaceuticals, Inc. (NASDAQ:TARS) Position Raised by Invesco Ltd.April 18, 2025 | marketbeat.com77,714 Shares in Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) Acquired by Federated Hermes Inc.April 15, 2025 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeMNMD, BLTE, TARS, and JANX Company DescriptionsBelite Bio NASDAQ:BLTE$60.18 +1.95 (+3.35%) Closing price 04/28/2025 04:00 PM EasternExtended Trading$60.18 +0.01 (+0.01%) As of 04/28/2025 06:51 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Belite Bio, Inc, a clinical stage biopharmaceutical drug development company, engages in the research and development of novel therapeutics targeting retinal degenerative eye diseases with unmet medical needs in the United States. The company's lead product candidate is LBS-008 (Tinlarebant), an orally administered once-a-day tablet for maintaining the health and integrity of retinal tissues in autosomal recessive Stargardt disease and geographic atrophy patients. It is also developing LBS-009, an anti-retinol binding protein 4 oral therapy that is in the preclinical development phase targeting liver disease, including non-alcoholic fatty liver disease, nonalcoholic steatohepatitis, and type 2 diabetes. Belite Bio, Inc was founded in 2016 and is based in San Diego, California. Belite Bio, Inc is a subsidiary of Lin Bioscience International Ltd.Janux Therapeutics NASDAQ:JANX$32.23 +1.18 (+3.80%) Closing price 04/28/2025 04:00 PM EasternExtended Trading$32.20 -0.03 (-0.09%) As of 04/28/2025 04:05 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Janux Therapeutics, Inc., a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr) platforms technology to treat patients suffering from cancer. The company's clinical candidates comprise JANX007, a prostate-specific membrane antigen or PSMA-TRACTr, which is in Phase 1 clinical trial in adults for the treatment of metastatic castration-resistant prostate cancer (mCRPC) and the vasculature of other tumors; and JANX008, an epidermal growth factor receptor or EGFR-TRACTr that is in Phase 1 clinical trial for the treatment of multiple solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, and renal cell carcinoma. Its development pipeline also consists of discovery stage products. The company has strategic research collaboration agreement with Merck Sharp & Dohme Corp. to develop TRACTr product candidates. Janux Therapeutics, Inc. was incorporated in 2017 and is headquartered in San Diego, California.Mind Medicine (MindMed) NASDAQ:MNMD$6.36 +0.13 (+2.09%) Closing price 04/28/2025 04:00 PM EasternExtended Trading$6.22 -0.14 (-2.12%) As of 04/28/2025 07:50 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Mind Medicine (MindMed) Inc., a clinical stage biopharmaceutical company, develops novel products to treat brain health disorders. The company's lead product candidates include MM-120, which is in phase 2 for the treatment of generalized anxiety disorder and attention deficit hyperactivity disorder; and MM-402, a R-enantiomer of 3,4-methylenedioxymethamphetamine, which is in phase I clinical trials for the treatment of core symptoms of autism spectrum disorder. Mind Medicine (MindMed) Inc. is headquartered in New York, New York.Tarsus Pharmaceuticals NASDAQ:TARS$49.72 -0.28 (-0.56%) Closing price 04/28/2025 04:00 PM EasternExtended Trading$49.74 +0.02 (+0.04%) As of 04/28/2025 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Tarsus Pharmaceuticals, Inc., a commercial stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for eye care in the United States. The company's lead product candidate is XDEMVY, a novel therapeutic for the treatment of blepharitis caused by the infestation of Demodex mites, as well as to treat meibomian gland disease. It is developing TP-04 for the treatment of rosacea; and TP-05 for Lyme prophylaxis and community malaria reduction. In addition, the company develops lotilaner to address diseases across therapeutic categories in human medicine, including eye care, dermatology, and other infectious disease prevention. Tarsus Pharmaceuticals, Inc. was incorporated in 2016 and is headquartered in Irvine, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Alphabet Rebounds After Strong Earnings and Buyback Announcement Could Selling Taiwan Semiconductor Be Buffett’s Biggest Regret? The Bear Market Has Only Just Started - Here's Why MarketBeat Week in Review – 04/21 - 04/25 3 Top Big Pharma Stocks Investing Over $100 Billion in the U.S. PepsiCo’s Stock Price is Disconnected From Reality: Time to Buy Bears Can Reap Big Benefits With These 3 Short ETF Bets Why Institutions Are Buying Super Micro Computer Stock Again Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
